AI Article Synopsis
- Abrocitinib is a new oral medication that specifically inhibits JAK-1, targeting inflammation pathways.
- It is currently approved for moderate-to-severe atopic dermatitis and shows potential for treating other inflammatory skin conditions.
- Clinical trials have confirmed its effectiveness and safety, but its future use will depend on practicality within the Indian healthcare context.
Article Abstract
Abrocitinib is a novel oral small molecule which acts as a selective JAK-1 inhibitor. Currently approved for use in moderate-to-severe cases of atopic dermatitis, this drug is gaining a rapid impetus for its use across various inflammatory dermatoses for its selective downstream action on cytokines of the JAK-1 pathway. Its efficacy and safety in atopic dermatitis has been established in phase 3 clinical trials. The future implication of this drug will depend largely on feasibility and practical use in Indian scenario.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616915 | PMC |
| http://dx.doi.org/10.4103/idoj.idoj_449_24 | DOI Listing |
Publication Analysis
Top Keywords
efficacy safety
8
atopic dermatitis
8
abrocitinib comprehensive
4
comprehensive review
4
review efficacy
4
safety dermatology
4
dermatology abrocitinib
4
abrocitinib novel
4
novel oral
4
oral small
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!